Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012', provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutic Products under Development, Key Players in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Overview, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Assessment
Summary
Global Markets Direct’s, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012', provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
- A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
- Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutic Products under Development, Key Players in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Overview, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline, Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
An Overview of Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Products under Development by Companies
Companies Involved in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Development
Genzyme Corporation
Amgen Inc.
Merck & Co., Inc.
ReGenX Biosciences, LLC
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0859 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KYNAMRO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Dormant Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Product Development Milestones
Featured News & Press Releases
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet
Apr 30, 2012: Aegerion Announces FDA Acceptance Of Lomitapide's New Drug Application For Review
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit
Mar 29, 2012: Genzyme And Isis Announce Submission Of NDA For KYNAMRO In Homozygous Familial Hypercholesterolemia
Mar 25, 2012: Amgen's PCSK9 Inhibitor Reduces LDL Cholesterol Up to 81% In Phase Ib Study
Mar 20, 2012: Aegerion Announces EMA Acceptance For Review Of Marketing Authorization Application For Lomitapide
Mar 15, 2012: Mylan Canada Receives Health Canada Approval For Generic Version Of Crestor
Mar 08, 2012: Aegerion Comments On FDA's Standard Review Classification For Lomitapide New Drug Application
Mar 05, 2012: Aegerion Pharmaceuticals Submits Marketing Applications For Lomitapide In US And EU
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2012
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Genzyme Corporation, H2 2012
Amgen Inc., H2 2012
Merck & Co., Inc., H2 2012
ReGenX Biosciences, LLC, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2012
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
An Overview of Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Products under Development by Companies
Companies Involved in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Development
Genzyme Corporation
Amgen Inc.
Merck & Co., Inc.
ReGenX Biosciences, LLC
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
MK-0859 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KYNAMRO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0524A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-145 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Dormant Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Product Development Milestones
Featured News & Press Releases
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet
Apr 30, 2012: Aegerion Announces FDA Acceptance Of Lomitapide's New Drug Application For Review
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit
Mar 29, 2012: Genzyme And Isis Announce Submission Of NDA For KYNAMRO In Homozygous Familial Hypercholesterolemia
Mar 25, 2012: Amgen's PCSK9 Inhibitor Reduces LDL Cholesterol Up to 81% In Phase Ib Study
Mar 20, 2012: Aegerion Announces EMA Acceptance For Review Of Marketing Authorization Application For Lomitapide
Mar 15, 2012: Mylan Canada Receives Health Canada Approval For Generic Version Of Crestor
Mar 08, 2012: Aegerion Comments On FDA's Standard Review Classification For Lomitapide New Drug Application
Mar 05, 2012: Aegerion Pharmaceuticals Submits Marketing Applications For Lomitapide In US And EU
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2012
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Genzyme Corporation, H2 2012
Amgen Inc., H2 2012
Merck & Co., Inc., H2 2012
ReGenX Biosciences, LLC, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2012
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
